MX2014005800A - Mutaciones del receptor notch humano y su uso. - Google Patents
Mutaciones del receptor notch humano y su uso.Info
- Publication number
- MX2014005800A MX2014005800A MX2014005800A MX2014005800A MX2014005800A MX 2014005800 A MX2014005800 A MX 2014005800A MX 2014005800 A MX2014005800 A MX 2014005800A MX 2014005800 A MX2014005800 A MX 2014005800A MX 2014005800 A MX2014005800 A MX 2014005800A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- notch receptor
- human notch
- receptor mutations
- solid tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La presente invención proporciona la identificación y caracterización de mutaciones NOTCH asociados con señalización de receptor mejorada. La presente invención proporciona métodos y kits para uso de los mismos. La presente invención proporciona adicionalmente métodos para tratar cáncer en un paciente que presenta un tumor sólido, en donde las células de tumor sólido comprenden un nivel elevado de NOTCH lCD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161560627P | 2011-11-16 | 2011-11-16 | |
US201261704006P | 2012-09-21 | 2012-09-21 | |
PCT/US2012/064969 WO2013074596A1 (en) | 2011-11-16 | 2012-11-14 | Human notch receptor mutations and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014005800A true MX2014005800A (es) | 2014-05-30 |
Family
ID=48430101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005800A MX2014005800A (es) | 2011-11-16 | 2012-11-14 | Mutaciones del receptor notch humano y su uso. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150316552A1 (es) |
EP (1) | EP2780354A4 (es) |
JP (1) | JP2015505668A (es) |
KR (1) | KR20140093991A (es) |
CN (2) | CN107056930A (es) |
AU (1) | AU2012339681A1 (es) |
BR (1) | BR112014011925A2 (es) |
CA (1) | CA2864197A1 (es) |
IL (1) | IL232491A0 (es) |
MX (1) | MX2014005800A (es) |
RU (1) | RU2014122048A (es) |
WO (1) | WO2013074596A1 (es) |
ZA (1) | ZA201404099B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
PL2307459T3 (pl) | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
US20130323266A1 (en) * | 2012-05-16 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch2/3 antibodies |
WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
US9822418B2 (en) * | 2013-04-22 | 2017-11-21 | Icahn School Of Medicine At Mount Sinai | Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis |
WO2015092614A1 (en) * | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
WO2015134627A1 (en) * | 2014-03-07 | 2015-09-11 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch1 antibodies |
EP2985289A1 (en) * | 2014-08-14 | 2016-02-17 | Miltenyi Biotec GmbH | Depletion of mouse cells for generic isolation of human cells upon xenotransplantation |
JP6827415B2 (ja) * | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ 5 インコーポレイテッド | 疾患の処置のための併用療法 |
CN105233289B (zh) * | 2015-10-29 | 2019-10-11 | 上海市肺科医院 | 一种用于治疗结核患者的组合物 |
CN107462722B (zh) * | 2015-11-16 | 2019-10-11 | 孙广玉 | 一种用于检测肿瘤的组合物 |
KR102477922B1 (ko) | 2016-03-16 | 2022-12-14 | 아베오미 코포레이션 | Il-25에 대한 중화 모노클로날 항체 및 그의 용도 |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
WO2022061595A1 (en) * | 2020-09-23 | 2022-03-31 | Xiang Li | Notch1 biomarkers for cancer therapy |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2023225345A1 (en) * | 2022-05-20 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Treating chemoresistant cancers with notch3 inhibitors |
WO2023234659A1 (ko) * | 2022-05-30 | 2023-12-07 | 재단법인 아산사회복지재단 | 퇴행성 턱관절염의 진단 또는 예후 예측용 유전자 마커 및 이의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524583A (zh) * | 1996-11-07 | 2004-09-01 | 能够表达Notch-配体的基因在制备用于免疫治疗的药物中的应用 | |
US20070077245A1 (en) * | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
JP2008228621A (ja) * | 2007-03-19 | 2008-10-02 | Univ Of Tokyo | びまん性大細胞性リンパ腫をサブタイプ分けする方法 |
CA2697106A1 (en) * | 2007-08-28 | 2009-03-12 | Donald Bergstrom | Expression profiles of biomarker genes in notch mediated cancers |
US8119366B2 (en) * | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
EP2260058A2 (en) * | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
PL2307459T3 (pl) * | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
-
2012
- 2012-11-14 WO PCT/US2012/064969 patent/WO2013074596A1/en active Application Filing
- 2012-11-14 MX MX2014005800A patent/MX2014005800A/es unknown
- 2012-11-14 CA CA 2864197 patent/CA2864197A1/en not_active Abandoned
- 2012-11-14 BR BR112014011925A patent/BR112014011925A2/pt not_active IP Right Cessation
- 2012-11-14 KR KR20147016087A patent/KR20140093991A/ko not_active Application Discontinuation
- 2012-11-14 JP JP2014542394A patent/JP2015505668A/ja active Pending
- 2012-11-14 CN CN201610930058.5A patent/CN107056930A/zh active Pending
- 2012-11-14 US US14/358,331 patent/US20150316552A1/en not_active Abandoned
- 2012-11-14 RU RU2014122048/10A patent/RU2014122048A/ru not_active Application Discontinuation
- 2012-11-14 CN CN201280067236.6A patent/CN104105702B/zh not_active Expired - Fee Related
- 2012-11-14 EP EP12850629.2A patent/EP2780354A4/en not_active Withdrawn
- 2012-11-14 AU AU2012339681A patent/AU2012339681A1/en not_active Abandoned
-
2014
- 2014-05-07 IL IL232491A patent/IL232491A0/en unknown
- 2014-06-05 ZA ZA2014/04099A patent/ZA201404099B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2780354A1 (en) | 2014-09-24 |
IL232491A0 (en) | 2014-06-30 |
CN107056930A (zh) | 2017-08-18 |
EP2780354A4 (en) | 2015-06-24 |
BR112014011925A2 (pt) | 2017-05-30 |
US20150316552A1 (en) | 2015-11-05 |
AU2012339681A1 (en) | 2014-06-19 |
WO2013074596A1 (en) | 2013-05-23 |
JP2015505668A (ja) | 2015-02-26 |
ZA201404099B (en) | 2015-11-25 |
CN104105702A (zh) | 2014-10-15 |
KR20140093991A (ko) | 2014-07-29 |
CN104105702B (zh) | 2016-11-23 |
CA2864197A1 (en) | 2013-05-23 |
WO2013074596A4 (en) | 2013-08-01 |
RU2014122048A (ru) | 2015-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
MX2020008976A (es) | Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1. | |
PH12014501844A1 (en) | Peptidomimetic macrocycles | |
MX2017005553A (es) | Terapia de combinacion para cancer. | |
MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
MX2017003797A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
WO2011141823A3 (en) | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists | |
NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
MX2015011428A (es) | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. | |
MX2019010098A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
WO2012135641A3 (en) | Aurora kinase inhibitors and methods of making and using thereof | |
WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
MX2014010713A (es) | Activacion de procaspasa 3 mediante terapia de combinacion. | |
MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MY160556A (en) | Neuregulin antagonists and use thereof in treating cancer | |
PL3460052T3 (pl) | Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu | |
MX362094B (es) | Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa. | |
MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
WO2013081645A3 (en) | Erbb3 mutations in cancer | |
WO2012109233A3 (en) | Methods for predicting recurrence risk in breast cancer patients | |
MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. |